PDCD1 and neoplasm: Our findings that an involution-targeted therapy, anti-PD-1, can mitigate the decrease in tumor growth and LVD that we observe after implantation during involution are consistent with our previous results showing that inhibition of COX-2 can decrease growth, invasion, LVD, and metastasis (3, 16).